CNV patients are responsive when switching anti-VEGF therapies

Article

Choroidial neovascularisation (CNV) patients are responsive when switching to bevacizumab or ranibizumab after they develop tachyphylaxis during anti-vascular endothelial growth factor (VEGF) therapy.

Choroidial neovascularisation (CNV) patients are responsive when switching to bevacizumab or ranibizumab after they develop tachyphylaxis during anti-vascular endothelial growth factor (VEGF) therapy, states a study in the British Journal of Ophthalmology.

A team led by Dr Srinivas Sadda, Doheny Eye Institute, Los Angleles, California, USA, included 26 eyes in the retrospective investigation. The records of CNV patients that were administered both bevacizumab and ranibizumab were reviewed to determine which patients had developed tachyphylaxis during treatment.

Tachyphylaxis was identified as OCT evidence of reduced exudation. Subretinal fluid (SRF), pigment epithelial detachment (PED) and cystoid macular oedema (CMO) were used to determine signs of exudation.

Of the 26 eyes featured in the study, 10 were treated with bevacizumab and then switched to ranibizumab in order to treat SRF, PED and CMO. Seven had occult CNV and three had predominantly classic CNV. There was no response in 1 eye of the occult CNV group after switching to ranibizumab treatment and there was a positive therapeutic response.

The remaining 16 eyes underwent ranibizumab treatment and then switched to bavacizumab. In this group there were 15 eyes with occult CNV and 1 with predominantly classic CNV. Of these eyes, 2 responded to ranibizumab treatment and 1 was unresponsive. Bevacizumab treatment caused 6 eyes to improve after one injection and 5 eyes to improve after 2 injections. The remaining 16 failed to respond.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.